HCV infects millions of people worldwide, and a protective vaccine is urgently needed. A study in Science Translational Medicine reports on the first-in-man study of an HCV vaccine. The researchers assessed a heterologous prime-boost vaccination strategy and found that this approach led to durable, broad, sustained and balanced T-cell responses. These responses were similar to those associated with viral control in natural infection.
References
Swadling, L. et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts and sustains functional HCV-specific T cell memory. Sci. Transl. Med. 6, 261ra153 (2014)
Rights and permissions
About this article
Cite this article
First-in-man study of HCV vaccine. Nat Rev Gastroenterol Hepatol 12, 5 (2015). https://doi.org/10.1038/nrgastro.2014.221
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2014.221
